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Objective: The current meta-analysis examines the effects of ketamine infusion on 
depressive symptoms over time in Major Depressive Disorder (MDD) and Bipolar Disorder 
(BD). 
Method: Following a systematic review of the literature, data were extracted from 21 
studies (n = 437 receiving ketamine) and analysed at four post infusion time-points (4 hours, 
24 hours, 7 days, 12-14 days). The moderating effects of several factors were assessed 
including: repeat/single infusion; diagnosis; open-label/participant-blind infusion; pre-
post/placebo-controlled design; and the sex of patients.  
Results: Effect sizes were significantly larger for repeat than single infusion at 4h, 24h, and 
at 7d. For single infusion studies, effect sizes were large and significant at 4h, 24h and 7d. 
Percentage of males was a predictor of anti-depressant response at 7 days. Effect sizes for 
open-label and participant-blind infusions were not significantly different at any time-point.  
Conclusion: Single ketamine infusions elicit a significant anti-depressant effect from 4 hours 
to 7 days; the small number of studies at 12-14 days post infusion failed to reach 
significance. Results suggest a discrepancy in peak response time depending upon primary 
diagnosis – 24 hours for MDD and 7 days for BD. The majority of published studies have 
used pre-post comparison; further placebo-controlled studies would help to clarify the 




Most current anti-depressants act on the monoamine systems of the brain and, crucially, 
are slow to elicit anti-depressant effects. By contrast, ketamine is an N-methyl-D-aspartate 
(NMDA) antagonist with purported rapid anti-depressant properties that are sustained 
beyond ketamine’s 3 hour half-life (Young, 2013; Salvadore & Singh, 2013). Ketamine is 
known to block NMDA receptors thereby affecting the action of glutamate, a major 
excitatory neurotransmitter in the brain (aan het Rot et al, 2012). Unlike traditional 
antidepressants, ketamine is administered intravenously. The first placebo-controlled study 
investigating ketamine for the treatment of depression was conducted by Berman et al 
(2000). Anti-depressant response to ketamine was maintained in four of the seven 
completers at the end of the 72-hour follow-up period.   
The prospect of using ketamine as an anti-depressant is a fascinating and exciting one, 
particularly in terms of its potential for alleviating depressive symptoms in individuals with 
treatment-resistant depression (Zarate et al, 2006; Kollmar et al, 2008; Murrough et al, 
2013; Liebrenz et al, 2007; Liebrenz et al, 2009; aan het Rot et al, 2010; Ibrahim et al, 2011; 
Ibrahim et al, 2012) and in reducing suicidal ideation, at least temporarily or in emergency 
situations (Price, 2009; DiazGranados, 2010a; Larkin & Beautrais, 2011; Price et al, 2014).  
Use of Ketamine to Treat Depression in Bipolar Disorder 
Ketamine has also been reported to alleviate depressive symptoms in treatment-resistant 
bipolar depression. DiazGranados et al (2010b) conducted a double-blind, randomised, 
crossover, placebo-controlled study using a single ketamine infusion combined with lithium 
or valproate therapy for individuals diagnosed with bipolar I or II depression. The results 
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indicated significantly fewer depressive symptoms within 40 minutes post-infusion and for 
up to 3 days in those receiving ketamine compared to placebo; after this time, depression 
scores began to increase, but remained below baseline level at day 14. Zarate et al (2012a) 
replicated the study conducted by Diazgranados et al (2010b). Analysis of the intent-to-treat 
sample showed a significant drug-by-time interaction for depression scores; participants 
receiving ketamine had significantly fewer depressive symptoms from 40 minutes to 3 days 
post infusion when compared to placebo. However, depression scores for placebo and 
ketamine did not significantly differ at days 7, 10, or 14. These findings are consistent with 
those of Berman et al (2000), wherein depression scores returned to baseline levels within 
1-2 weeks post infusion. 
Safety, Efficacy and Durability of Repeated Ketamine Infusions 
Since the effects of ketamine appear to be relatively short-lived, repeated ketamine 
infusions may potentially increase the duration of anti-depressant response. The tolerability 
and safety of repeated ketamine infusions in treatment-resistant depression was 
investigated by aan het Rot et al (2010) alongside the efficacy and clinical benefit of 
ketamine in treating depression. Depression scores were assessed at baseline and up to 24 
hours post infusion. At 24 hours following a single intravenous ketamine (0.5mg/kg) 
infusion, 90% of participants met the response criterion (≥50% reduction in MADRS score) 
and were eligible for the second phase. These participants received five additional infusions 
of ketamine. The majority of participants (89%) who had received multiple ketamine 
infusions were found to relapse within an average of 30 days after the first infusion (an 
average of 19 days after the 6th infusion). Notably, one participant who had received six 
infusions demonstrated reduced depressive symptoms for more than four weeks and 
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another for almost seven weeks; another continued to have decreased depressive 
symptoms for over three months.  
The durability of response in individuals with treatment-resistant depression following 
repeated ketamine infusions was recently investigated in a larger treatment group (n = 24) 
by Murrough et al (2012). It should be noted that the results for ten of the 24 participants in 
Murrough et al’s (2012) study were previously reported by aan het Rot et al (2010). 
Participants received up to six infusions of ketamine (0.5mg/kg) on a Monday-Wednesday-
Friday schedule over 12 days. Participants meeting response criteria (≥50% reduction in 
MADRS score) following multiple infusions were tracked for a maximum of 83 days or until 
relapse (<50% improvement in MADRS score compared with baseline for two consecutive 
assessments). Overall, approximately 71% of participants responded to ketamine. The 
median time to relapse after the last ketamine infusion was 18 days and so, the duration of 
anti-depressant effect for repeat infusions may not extend much beyond that of a single 
infusion as identified by Diazgranados et al (2010).  
Rasmussen et al (2013) conducted an open-label study to determine whether serial 
infusions of ketamine elicited better response and remission rates than single infusions. 
Participants received up to four ketamine infusions twice-weekly (for up to two weeks). If a 
participant met remission criteria (MADRS score <9) on the morning after an infusion or on 
the morning of the next scheduled infusion, they received no further infusions. Half of 
participants met remission criteria during the study. Rasmussen et al (2013) inferred that 
serial infusions may be more successful than a single infusion in reducing depressive 
symptoms. Despite taking anti-depressant medication, however, throughout a four-week 
follow-up period, symptom remission was maintained in only 20% of participants at the end 
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of the follow-up period. The advantage of repeated over single ketamine infusion is 
questionable since the seemingly prolonged anti-depressant effect of repeated infusions is 
minimal in duration. Furthermore, and crucially, none of these studies (aan het Rot et al, 
2010; Murrough et al 2012; or Rasmussen et al 2013) employed a control group with which 
to compare relapse times. 
Objectives of the Current Study 
To the authors’ knowledge, no meta-analysis has synthesized the published clinical trial data 
on ketamine as an anti-depressant. The key questions are: does ketamine have an 
immediate effect in reducing depressive symptoms?; Are the anti-depressant effects of 
ketamine sustained over time?; Are repeat infusions more effective in reducing depressive 
symptoms?; Do primary diagnosis and experimental design moderate the impact of 
ketamine on depressive symptoms? Finally, some evidence from studies on rats suggests a 
higher sensitivity of female rats to a low dose of ketamine (Carrier and Kabbaj 2013). Thus, 
we will also examine for differences in the anti-depressant effect of ketamine depending 
upon the sex of the patient.  
 
Method 
Identification and Selection of Studies 
The review was conducted in accordance with PRISMA guidelines (Moher et al, 2009). A 
systematic search was conducted in Web of Science, Science Direct, and PubMed using the 
terms ‘ketamine’ AND ‘depression’. In Web of Science and Science Direct, abstracts, title, 
and keywords were searched; in PubMed all fields were searched. The subject areas in 
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Science Direct to which the search was restricted were: Arts and Humanities; Biochemistry, 
Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutical Science; 
Psychology; Social Science. As the first clinical trial of ketamine for the treatment of 
depression was conducted in 2000, all years from 2000 up to January 2015 were included in 
the search.  
Criteria for Inclusion of Studies 
Studies were included in the meta-analysis if at least one infusion of ketamine was 
administered for the treatment of depression; and primary diagnosis could include Major 
Depressive Disorder (MDD) or Bipolar Disorder (BD). Included studies were also required to 
report on depressive symptoms using a standardised measure of depression, such as the 
Montgomery-Åsberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating 
Scale (HDRS) and to include eight or more participants. A summary of the selection process 
is given in Figure 1. 
 
[Figure 1 about here] 
 
Data Extraction  
Data were extracted from studies meeting the criteria outlined above. Where data were 
incomplete or unclear, we contacted authors for clarification or additional data. In some 
cases, additional data could not be obtained after enquiring with authors and such studies 
were consequently excluded from the meta-analysis. Meta-analysis was conducted for four 
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post infusion time-points (4 hours, 24 hours, 7 days, and 12-14 days). Where studies used a 
control group, the effect sizes were calculated for placebo versus ketamine; where no 
control group was used, the effect sizes were calculated for baseline depression scores 
versus scores at each time point.  All data analysis was conducted using Comprehensive 
Meta-Analysis Version 2.0 (http://www.meta-analysis.com/). Effect sizes were calculated 
using Hedge’s g, i.e. the standardised difference between means, corrected for the 
tendency towards over-estimation in small studies using a random effects model. Effect 
sizes were described using Cohen’s convention wherein an effect size of 0.20 was 
considered small, 0.50 moderate, and 0.80 large. 
 
Statistical Heterogeneity 
We assessed heterogeneity using the I2 value, which estimates the amount of total variation 
that attributable to heterogeneity. An I2 value of 0-40% suggests that heterogeneity may not 
be important, 30-60% may represent moderate heterogeneity, 50-90% may represent 
substantial heterogeneity, and 75-100% may represent considerable heterogeneity (see 
Cochrane, 2011). 
 
Risk of Bias 
Studies involved in the meta-analysis were assessed for possible bias. A study was 
considered to have a low risk of bias if a control group was employed, if allocation of 
participants to control and experimental groups was adequately randomised, and if there 
was no evidence of conflict of interest. Medium risk of bias was assigned if a control 
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condition was employed within an ABBA design (blindness may have been compromised by 
the ‘high’ associated with ketamine infusions), if there was evidence of adequate 
randomisation of participants to control and experimental groups (where a control group 
was employed), if selection of participants was randomised and if there was a potential 
conflict of interest. High risk of bias was assigned if a study did not employ a control group, 
demonstrated little evidence of random selection of participants, and a potential conflict of 
interest was identified. 
 
Effects of Moderators 
The effects of several factors were examined: namely, experimental design (pre-post and 
placebo-controlled), diagnosis (MDD, BD, mixed/unknown), number of infusions (single or 
repeated), and infusion delivery (open-label or participant-blind). A meta-regression was 




Publication bias was examined using Fail Safe N, Duval and Tweedie’s trim and fill (Duval & 
Tweedle, 2000), Begg and Mazumdar’s Rank Correlation Test (Begg and Mazumdar, 1994), 
and Egger’s test of the intercept (Egger, Davey Smith, Schneider & Minder, 1997). 
 
Results 
Identification and Selection of Studies 
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The total number of studies (K) selected was 21, of which 17 were single infusion studies. 
The majority of studies collected and reported data at 4h (K = 11) and 24h (K = 13); a smaller 
number of studies reported data at 7d (K = 6) and at 12-14d (K = 4). For single infusion 
studies, results were reported for 9 studies at 4 hours, for 11 studies at 24 hours, for 5 
studies at 7 days, and for 2 studies at 12-14 days post infusion. 
Risk of Bias 
[Table 1 about here] 
 
Overall Pooled Effect Sizes 
Overall pooled Hedge’s g values were large and significant at all time-points (see Table 2). 
No significant differences in effect sizes emerged between any time-points (4h vs 24h: p = 
0.36; 4h vs 7d: p = 0.47; 4h vs 12-14d: p = 0.55; 24h vs 7d: p = 0.45; 24h vs 12-14d: p = 0.73; 
7d vs 12-14d: p = 0.31). The heterogeneity across studies was large and significant at all 
time-points (see Table 2). The forest plot for all time-points is given in Figure 2. 
[Table 2 about here] 
[Figure 2 about here] 
Moderating Effect of Single and Repeat Infusions 
At all time-points the effect sizes for repeat infusions were larger than for single infusions, 
and significant at 4 hours (-3.34 vs -1.11, p = 0.001), 24 hours (-4.16 vs -1.11, p = 0.000), and 
at 12-14  days (-2.95 vs -0.85, p = 0.012) post infusion, but not at 7 days (-1.96 vs -0.88, p > 
0.05); however, the number of repeat infusions studies is limited at each of these time-
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points (K= 2, 2, 1, and 2, respectively). Single infusion studies were significant at 4h, 24h, 
and at 7d. A large effect size was determined at 12-14d, but did not reach significance 
(possibly because of insufficient available studies; see Table 3). Comparison of single 
infusion studies revealed no significant differences in effect sizes between time-points (4h 
vs 24h: p = 0.59; 4h vs 7d: p =0.43; 4h vs 12-14d: p = 0.71; 24h vs 7d: p = 0.16; 24h vs 12-
14d: p = 0.55; 7d vs 12-14d: p = 0.85).  
[Table 3 about here] 
 
Single Infusion: Moderating Effect of Diagnosis 
We examined the impact of moderators for single infusion studies but insufficient data were 
available for repeat infusion studies to permit similar analyses (see Cochrane, 2011).  
For MDD, effect sizes ranged from moderate at 7d (-0.53) to large at 4h (-1.03) and 24h (-
1.35). For BD, effect sizes ranged from moderate at 24h (-0.64) to large at 4h (-0.80) and at 
7d (-1.51) post infusion; a large but not significant effect size was determined at 12-14 days 
post infusion (see Table 4). The effect sizes for MDD and BD did not significantly differ at 4 
hours post infusion (p = 0.30), but were significant at 24 hours (p < 0.001) and 7 days (p < 
0.001) post infusion. The effect size for MDD was largest at 24h, whereas the effect size for 
BD was largest at 7d. Lack of studies permitted comparison of MDD and BD at 12-14 days 
since no MDD studies measured at this time-point.  
[Table 4 about here] 
Single Infusion: Moderating Effect of Experimental Design 
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For pre-post design, the effect sizes were large and significant at all post infusion time-
points (see Table 5). For placebo-controlled design, effect sizes ranged from small to large; 
the effect sizes were significant at 4 hours, 24 hours and 7 days post infusion, but not at 12-
14 days post infusion; however, only one placebo-controlled study was available at 4 hours 
and at 12-14 days post infusion so the results must be interpreted with caution. The 
difference between effect sizes for pre-post and placebo-controlled design was not 
significant at 4 hours (p = 0.10), 24 hours (p = 0.26) or 7 days (p = 0.41) post infusion, but 
was significant at 12-14 days (p < 0.001); however, only one study was available for each 
design at 12-14 days post infusion.  
[Table 5 about here] 
Single Infusion: Moderating Effect of Open-Label and Blind Infusions 
For open-label infusions, the effect sizes ranged from small to large and, with the exception 
of 7 days post infusion, all effect sizes were significant (4h: -1.03, CI95 = -1.39, -0.68, K = 7; 
24h: -1.57, CI95 = -2.32, -0.82, K = 3; 7d: -0.25, CI95 = -0.66, 0.16, K = 1). No open-label single 
infusion studies were available at 12-14 days. For participant-blind infusions, the effect sizes 
ranged from small to large (4h: -0.80, CI95 = -1.05, -0.56, K = 1; 24h: -1.00, CI95 = -1.29,   -
0.71, K = 7; 7d: -0.68, CI95 = -0.99, -0.36, K = 2; 12-14d: -0.21, CI95 = -0.44, 0.02, K = 1). The 
effect size at 12-14 days was not significant; effect sizes at all other time-points were 
significant. The difference between effect sizes for open-label and participant-blind 
infusions was not significant at any time-point (4h: p = 0.30; 24h: p = 0.17; 7d: p = 0.11).  
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Single Infusion: Effect of Sex 
A meta-regression was conducted with percentage of males as a predictor of effect size, 
with no significant effects determined at 4h (p = 0.60) or 24h (p = 0.08). However, a 
significant positive relationship between percentage males and effect size was determined 
at 7d (p = 0.008); however, only four data points were available at this time-point. Meta-
regression could not be conducted at 12-14 days post single ketamine infusion due to an 
insufficient number of studies. 
Single Infusion: Publication Bias 
Publication bias (see Table 6) was examined using Fail Safe N, Duval and Tweedie’s trim and 
fill (Duval & Tweedle, 2000), Begg and Mazumdar’s Rank Correlation Test (Begg and 
Mazumdar, 1994), and Egger’s test of the intercept (Egger, Davey Smith, Schneider & 
Minder, 1997). The results across all the tests indicate publication bias at 4 hours and 24 
hours for single infusion studies. 
[Table 6 about here] 
Discussion 
The results of the meta-analysis suggest that ketamine reduces depressive symptoms with 
large effect sizes at every time-point analysed (4 hours, 24 hours, 7 days and 12-14 days). 
The relative stability of the effect size across time-points suggests a sustained anti-
depressant response to ketamine at least up to two weeks post infusion as examined in 
clinical trials to date. 
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Turning to single infusion studies, large effects emerged at 4 hours and at 24 hours, 
confirming the reported rapid reduction in depressive symptoms, and also at 7 days; a large 
effect at 12-14 days failed to reach significance.  The lack of longer term effect is consistent 
with reports of relapse within 1-2 weeks for a single infusion (Zarate et al, 2006); however, 
few single infusion studies have assessed up to 12-14 days post-infusion (K = 2). No 
significant difference in effect size emerged between any time-points for single infusions. As 
expected, effect sizes for repeat infusions were larger than for single infusions and differed 
significantly at 4 hours, 24 hours and at 7 days. It must be noted that the number of repeat 
infusion studies was limited and further studies are required.  
Moderating Effects of Diagnosis 
Although effect sizes for Major Depressive Disorder (MDD) and Bipolar Disorder (BD) were 
moderate to large, some differences emerged in responsiveness. Following a single infusion, 
the effect for MDD at 24 hours was significantly larger than for BD; at 7 days BD showed a 
significantly larger effect size than MDD. These findings hint that the anti-depressant effect 
of a single ketamine infusion may vary according to the primary diagnosis, although this 
interpretation is limited by the small number of studies available, particularly at 7 days (K = 
3 and K = 2 for MDD and BD, respectively).  
Moderating Effects of Experimental Design 
Single infusion pre-post comparisons resulted in larger effect sizes than placebo-controlled 
designs, although the difference was significant only at 12-14 days. Interpretations are 
somewhat limited by the small number of placebo-controlled studies at each time-point. 
Furthermore, all studies employing pre-post designs also used open-label infusions and this 
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may have affected the outcome owing to the potential of an expectancy bias. Further blind 
placebo-controlled studies, such as that carried out by Murrough et al (2014), are required 
to confirm the findings.  
Moderating Effects of Open-Label and Participant-Blind Infusions 
As might be expected, effect sizes in open-label trials were larger than for participant-blind 
trials. The difference reached significance at 12-14 days with a large effect size for open-
label infusions, although it consisted of comparing just two studies. Indeed, the lack of 
significant differences at other time-points may reflect the small numbers of studies being 
compared (with just one blind trial at 4 hours, 7 days, and 12-14 days).  Consideration of 
further interpretations is, however, required. In particular, the larger effect sizes for open-
label infusion may arise as a result of expectancy bias, with knowledge of having received 
ketamine impacting participants’ reported decrease in depressive symptoms. Similarly, 
those assessing symptoms may also have an expectancy bias for open-label infusions which 
may affect how they make MADRS and HDRS ratings.  Conversely, and noted by Berman et 
al (2000) in the first published trial, blinding itself is likely to be compromised given the 
psychotomimetic effects of ketamine, especially with the lack of any active controls in 
studies.  Indeed, at doses comparable to those used in depression studies reported here, 
subanaesthetic ketamine does generate self-reported “mystical-type phenomena” (Dakwar 
et al, 2014).  These authors remark that “An intriguing but unexplored question is whether 
the psychoactive effects of ketamine influence its efficacy through psychological 
mechanisms.” (p 153).  Apart from needing more placebo-controlled studies per se, future 
studies need to explore potential active controls to ensure that blindness to a ketamine 
infusion is preserved and thus provide more accurate conclusions regarding ketamine’s 
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specific effect on depressive symptoms. Second, confounding occurs as all open-label trials 
have utilised a pre-post design whereas placebo-controlled design was employed in all 
participant-blind studies. Therefore, we cannot eliminate experimental design differences as 
the cause of the discrepancy in effect sizes.  As it is not possible to extricate the moderating 
effects of experimental design from nature of administration of ketamine, we cannot 
currently determine if one or both factors have a moderating effect on depression scores.  
Effect of Sex 
A significant effect of sex was found at 7 days post-infusion, but not at any other time-point, 
indicating that percentage of males is a predictor of response. This finding hints at a bigger 
symptom reduction perhaps in men, but the finding is for only a few studies (K = 4) and only 
at that one time point - a finding that needs to be examined in future studies. This finding is 
not consistent with the higher sensitivity of female rats to a low dose of ketamine (Carrier & 
Kabbaj, 2013). Additional studies are required to confirm whether there is an effect of sex 
on the outcome of ketamine infusion and what exactly that effect is, as the current meta-
analysis and the effect of ketamine in rats appear to contradict each other. 
Limitations of the Current Meta-Analysis 
The main limitation of this meta-analysis is the relatively small number of studies with 
useable data (K = 21), particularly for repeated ketamine infusion (K = 4). Although most 
studies reported results at 4 (K = 11) and 24 hours (K = 13) post-infusion, the results suggest 
an anti-depressant effect of ketamine may last for up to 14 days.  
What happens beyond 14 days is unknown.  The reported relapse rates have varied across 
studies. Ibrahim et al (2012) reported an average time to relapse of 13.2 days. Mathew et al 
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(2010) reported that for participants prescribed post infusion placebo the average time to 
relapse, as indicated by MADRS scores, was 22 days. Of the participants who received post-
infusion riluzole (a glutamate-modulating agent expected to maintain the anti-depressant 
effects of ketamine) in Mathew et al’s (2010) study, 80% relapsed compared to 50% of those 
taking post-infusion placebo. Furthermore, 17% of those taking riluzole and 50% of those 
taking placebo continued to meet response criteria at 32 days post infusion. Thus, riluzole 
appears to be less effective at maintaining anti-depressant response when compared to 
placebo. The results of Mathew et al (2010) imply that an anti-depressant response of up to 
32 days post-ketamine is possible. It must be noted, however, that those assigned to the 
placebo/riluzole trial had maintained a post-infusion anti-depressant response for 72 hours. 
As this group is highly selective, it is not representative of all individuals receiving ketamine 
infusion and thus the likelihood is that an anti-depressant effect of 32 days duration is more 
likely to be the exception rather than the rule. 
It is plausible that the duration of the anti-depressant effect of ketamine may extend 
beyond 14 days, but with most studies reporting ketamine’s anti-depressant effects only up 
to 24 hours, we cannot currently determine if this is the case. The results of the meta-
analysis show that repeat infusions elicit larger effect sizes when compared to a single 
infusion in the three published repeat infusion studies we examined. The larger effect sizes 
for repeat infusions are consistent with the exacerbated effects of ketamine with repeated 
exposure found in rats (Trujillo et al, 2008). Nonetheless, two of the repeat infusion studies 
used in this meta-analysis selected participants who had previously responded to ketamine. 
Specifically, participants who had responded to two prior infusions of ketamine in aan het 
Rot et al’s (2010) study were selected to receive additional infusions. Although eight of the 
18 
 
nine participants in this study continued to respond for an average of 30 days from the first 
infusion, such an effect might not be found outside of this highly selective group. 
Furthermore, Price et al (2009) reported repeat infusion data for participants who had 
responded to a single ketamine infusion and subsequently received multiple infusions. 
Additional repeat infusion studies are required to ascertain the effect of multiple ketamine 
infusions in a larger and less selective population. 
The results of the current meta-analysis indicate that the anti-depressant effects of 
ketamine last up to 14 days after a single infusion. For repeat infusions, the median time to 
relapse has been reported as 18 days (Murrough et al 2013) and 19 days (aan het Rot et al 
2010) after the last in a series of 6 infusions.  In both cases, the duration of response for 
repeat infusion studies is only slightly longer than the apparent 14-day duration for single 
infusion studies as assessed by this meta-analysis. Further investigation is required to see if 
repeat infusions, administered over a short period of time, have any significant long-term 
benefit over a single infusion.  
Although previous experience of ketamine was used as an exclusion criterion in some trials 
(e.g. Zarate et al 2012a), others included patients who had participated in previous 
ketamine trials. Salvadore et al (2012) included 4/14 patients tested by Salvadore et al (2009 
and 2010); and Salvadore et al (2010) included 7/15 patients previously assessed by 
Salvadore et al (2009). More notably perhaps, aan het Rot et al (2010) assessed the same 10 
patients as in the trial by Mathew et al (2010). Although both studies tested the same 
participants using a ketamine infusion of 0.5 mg/kg over 40 min, the two studies revealed 
quite different effect sizes at 24 hours, an effect size of -4.8 for aan het Rot et al (2010) and -
2.05 for Mathew et al (2010). The use of known ketamine responders by aan het Rot et al 
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(2010) may well have inflated the ketamine effect, especially as the study was also non-
blind. Studies assessing those who have had prior exposure to ketamine have also employed 
pre-post designs and, so, are not using randomised samples or controls per se. Rather, those 
studies are selecting participants who have already been shown to exhibit large, albeit 
temporary, symptomatic reduction e.g. in aan het Rot (2010) patients had previously (in 
Mathew et al 2010) shown a 50% reduction in the severity of their depressive symptoms for 
at least 24 hours. Given the larger response to repeated administration of ketamine, this is 
an important limitation of non-randomised open-trials. Moreover, studies using known 
responders are, of course, primed to produce significant effects. 
The Future of Ketamine as a Treatment for Depression 
Our meta-analysis reveals peak time differences in elicited response according to primary 
diagnosis; this requires further investigation. If primary diagnosis affects the anti-depressant 
outcome of ketamine infusion, this may have an impact on how ketamine is used in the 
treatment of depressive symptoms and the groups for whom it will be effective. For 
example, Niciu et al (2013) reported two cases of suicidal ideation, dysphoria and anxiety 
within 24 hours of a single ketamine infusion in two patients with a diagnosis of obsessive 
compulsive disorder (OCD) and a history of, but not current, MDD. These findings indicate 
the importance of considering potential comorbid diagnoses that may occur alongside 
depression. The meta-analysis also highlighted a need for randomised control trials to 
establish the safety, efficacy, and durability of response of single and of repeated ketamine 
infusions. Placebo-controlled studies where the ‘blindness’ of the infusion is maintained, 
such as Murrough et al (2014) where midazolam was employed as a control, are particularly 
important to understanding ketamine’s anti-depressant effects.  
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Although ketamine has been employed as an anaesthetic since the 1960s (Salvadore & 
Singh, 2013), repeated ketamine infusions in rats have elicited an escalated response 
consistent with sensitisation (Trujillo et al 2008). Sensitisation to ketamine was greater 
when rats were exposed to distinct environmental cues and this suggests that repeated 
exposure to ketamine could result in addiction. A 1-year longitudinal study of recreational 
users found that frequent users were more likely to demonstrate dissociative and delusional 
symptoms, along with cognitive impairments affecting spatial working memory and pattern 
recognition memory tasks (Morgan et al 2010). Interestingly, elevated depression scores 
were also reported in both frequent and abstinent ketamine users across the 12-month 
period (Morgan et al, 2010). A more recent study found that ketamine users showed 
elevated delusional, schizotypal and depressive symptoms when compared to controls 
(Freeman et al, 2013). The addictive potential of repeated ketamine exposure must be 
addressed (Morgan & Curran, 2012; Trujillo et al, 2008; Hillemacher, 2007), as should any 
long-term adverse effects extending beyond the infusion period (Freeman et al, 2013). None 
of the studies included in the current meta-analysis documented major adverse effects, but 
side-effects such as transient headache, dizziness and nausea were commonly reported; 
such side-effects reportedly dissipated fairly quickly, usually once the infusion was complete 
(aan het Rot et al 2010; Abdallah et al 2012; Thakurta et al, 2012; Murrough et al 2013). 
Many studies also documented the dissociative effects of ketamine in participants 
(Diazgranados et al 2010; Ibrahim et al 2011;Larkin et al 2011; Zarate et al 2012a; Loo et al 
2012; Murrough et al 2012, 2013; Carlson et al 2013; Sos et al 2013; Lapidus et al 2014) and 
increased, if somewhat mild, psychotomimetic experiences (Salvadore et al 2009, 2010; 
Mathew et al 2010; Larkin et al 2011; Loo et al 2012; Murrough et al 2012, 2013 ; Sos et al 
2013; Lapidus et al 2014). As most studies have not followed participants beyond 24 hours 
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post-infusion, any long-term side-effects and addictive potential of ketamine infusion in the 
treatment of depression are difficult to determine . Future studies should address this key 
issue. 
Trapid anti-depressant effects of ketamine may be well-placed in situations where an 
immediate alleviation of depressive symptoms is required; however, it does not have a 
significant anti-depressant effect on everyone. Murrough et al (2013) found that MADRS 
score at 4 hours post infusion was an indicator of response or non-response; lack of a 
response to a single ketamine infusion was an adequate predictor of lack of response to 
subsequent infusions. Several studies have reported a response rate of around 40% at 4 
hours post infusion (Ibrahim et al, 2012; Phelps et al, 2009; Zarate et al, 2012b; Cornwell et 
al, 2012; Sos et al, 2013; Lapidus et al, 2014) while some studies have reported response 
rates of approximately 60-70% between 4 hours and 24 hours following ketamine infusion 
(Zarate et al, 2012b; Duncan et al, 2013; Mathew et al, 2010; Zarate et al, 2006; Murrough 
et al, 2013). Conversely, Rybokowski et al (2013) determined response rates of only 4% at 6 
hours post infusion and 24% at 24 hours post infusion in participants with a primary 
diagnosis of BD. The disparity in response rates highlights the need for future studies 
incorporating larger samples to determine the average response rate for the target 
population; primary diagnosis must also be considered. Furthermore, certain groups have 
shown stronger anti-depressant response to ketamine than others and this also requires 
consideration. For example, Phelps et al (2009) and Luckenbaugh et al (2012) reported that 
ketamine infusion elicited a significantly greater reduction in MADRS scores for participants 
with a family history of alcoholism, compared to participants without a family history of 




The present meta-analysis has established ketamine as an effective and rapid treatment for 
depression in the short-term, impacting depressive symptoms from 4 hours and, as far as 
we know, for up to two weeks post infusion in participants with a primary diagnosis of MDD 
or BD. When time to relapse is taken into account, repeat infusion does not appear to 
extend the duration of anti-depressant effect. Thus, single and repeat ketamine infusions 
appear to be equally effective in reducing depressive symptoms; however, the small number 
of repeat infusion studies available hinders the interpretation of this finding. More 
adequately controlled studies are necessary, especially randomised control trials with a 
control group and, preferably, some kind of active control. The extent to which ketamine 
can be used as an emergency treatment and, indeed, as a longer-term treatment for 
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Figure  1. Flow diagram of the study selection process 
 
Records identified in database search 
PubMed (n = 514); Science Direct (n = 
148); Web of Science (n = 641) 
Additional records identified through 
other sources (aan het Rot et al, 2012) 
(n = 27) 
Records screened by title 
(n = 1303) 
Records after duplicates removed 
PubMed (n = 136); Science Direct (n 
= 39); Web of Science (n = 123) 
Records excluded by title  
(n = 463) 
Animal studies: 237 
Non-depression-related studies: 
197 
Full-text articles assessed for 
eligibility (n = 81) 
Full-text articles excluded, 
incl. reviews, case studies, 
animal studies (n = 36) 
Studies included in qualitative 
synthesis (n = 24) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 21) 
Records screened by abstract 
(n = 298) 
Records excluded 
(n = 224) 
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Table 1 Table of Analysis of Risk of Bias in Studies Used in the Meta-Analysis 








Zarate et al (2006) 18 33 N Y Y  N Control 
condition 
Yes Yes No None Low 
Salvadore et al (2009) 11 64 Y N N N No N/A No No Yes Medium 




N Y N N No N/A Unknown No Yes  Low 
aan het Rot et al (2010) 9 50 Y Y N N No N/A Unknown No Yes High 
Salvadore et al (2010) 15 Unknown Y N N N No N/A No No Yes Medium 
Mathew et al (2010) 26 61.5 N Y N N Yes  Yes No No Yes  Medium 
Diazgranados et al (2010) 18 33 N Y N Y Yes Yes Yes Yes Yes  Low 
Ibrahim et al (2011) 17(E); 
23(NE) 
59(E); 61(NE) Y N N N ECT-resist vs 
no-ECT 
No No No None Medium 
Larkin et al (2011) 14 Unknown Y N N N No N/A Unknown No Unknown Medium 
Salvadore et al (2012) 14 64 Y N N N No N/A No No None Medium 
Zarate et al (2012a) 15 47 Y Y N N Yes Yes Yes Yes Yes  Medium 
Thakurta et al (2012) 20 Unknown Y N Y N No N/A No No None Medium 
Abdallah et al (2012) 8 56 N Y N N Yes Yes Yes No Unknown Low 
Loo et al (2012) 22 50 N N Y Y Yes Yes Yes No None Low 
Murrough et al (2012) 24 62.5 Y Y N N No N/A No No Yes  High 
Carlson et al (2013) 20 70 Y Y N N No N/A No No Yes  Medium 
Rybakowski et al (2013) 25 16 N Y Y Y No N/A Unknown No None Medium 
Permoda-Osip et al 
(2013) 
10 0 N N Y N No N/A Unknown No Unknown Medium 
Murrough  et al (2013) 47(K) 45(K) N Y N N Yes Yes Yes Yes Yes Medium 
Sos et al (2013) 27 50 N Y Y N CO Yes Yes Yes None Low 
Lapidus et al (2014) 18 50 - Y Y N CO Yes Yes Yes Yes Medium 
ITT=Intention-To-Treat; E=ECT; NE=no ECT; S=single infusion; R=repeat infusion; K=Ketamine; O = Overall; CO= crossover design 
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4h 11 -1.29 -1.66 -0.92 <0.001 81.73 
24h 13 -1.24 -1.56 -0.93 <0.001 79.81 
7d 6 -1.06 -1.57 -0.55 <0.001 81.02 
12-14d 4 -1.67 -2.85 -0.49 0.006 93.65 
K = Number of Studies; CI = 95% Confidence Interval 
 
Table 3. Effect Sizes for Single and Repeated Infusions 
 
















4h 9 -1.11 -1.44 -0.78 <0.001 79.65  2 -3.34 -4.58 -2.10 <0.001 0 
24h 11 -1.11 -1.38 -0.83 <0.001 75.53  2 -4.16 -5.67 -2.64 <0.001 0 
7d 5 -0.88 -1.35 -0.41 <0.001 75.00  1 -1.96 -2.66 -1.25 <0.001 0 
12-14d 2 -0.85 -2.17 0.46 0.203 94.50  2 -2.95 -5.65 -0.24 0.033 84.36 
K = Number of Studies; CI = 95% Confidence Interval 
35 
 
Table 4. Single Infusion: Moderating Effect of Diagnosis 


















4h 7 -1.03 -1.39 -0.68 <0.001  1 -0.80 -1.05 -0.56 <0.001 
24h 7 -1.35 -1.72 -0.99 <0.001  3 -0.64 -0.79 -0.49 <0.001 
7d 3 -0.53 -0.82 -0.24 <0.001  2 -1.51 -1.99 -1.03 <0.001 
12-14d 0 - - - -  2 -0.85 -2.17 0.46 0.20 
K = Number of Studies; CI = 95% Confidence Interval 
 
Table 5. Moderating Effects of Pre-Post Comparison and Placebo-Controlled Single Infusion Studies 



















4h 8 -1.21 -1.63 -0.79 <0.001  1 -0.80 -1.05 -0.56 <0.001 
24h 5 -1.33 -1.91 -0.75 <0.001  6 -0.96 -1.26 -0.66 <0.001 
7d 3 -1.12 -2.10 -0.13 0.03  2 -0.68 -0.99 -0.36 <0.001 
12-14d 1 -1.55 -2.12 -0.98 <0.001  1 -0.21 -0.44 0.02 0.07 





Table 6. Table of Publication Bias for Single Infusion Studies  
  K Unadjusted ES (95% CI) 
Trim and fill  
Begg & Mazumdar’s test Egger’s test 
adjusted ES (95% CI) 
4h 9 -1.11 (-1.44, -0.78) -1.27 (-1.69, -0.86) z = 1.77 p = 0.04 t = 3.05 p = 0.02 
24h 11 -1.11 (-1.38, -0.83) -0.97 (-1.25, -0.70) z = 2.65 p = 0.004 t = 4.81 p = 0.0005 
7d 5 -0.88 (-1.35, -0.41) -0.88 (-1.35, -0.40) z = 0.73 p = 0.23 t = 2.05 p = 0.07 








Study name Subgroup within study Comparison Outc ome Time point Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-V alue
00d4h aan het Rot et al (2010) Repeat infusion (Responders only) Pre/Post MADRS 00d4h -3.634 -5.414 -1.855 0.000
00d4h Zarate et al (2012a) Single infusion Placebo/Ketamine MADRS 00d4h -0.804 -1.050 -0.557 0.000
00d4h Carlson et al (2013) Single infusion Pre/Post MADRS 00d4h -1.013 -1.538 -0.488 0.000
00d4h Murrough et al (2012) Repeat infusions (Responders only) Pre/Post MADRS 00d4h -3.060 -4.787 -1.332 0.001
00d4h Salvadore et al (2009) Single infusion Pre/Post MADRS 00d4h -0.989 -1.673 -0.304 0.005
00d4h Salvadore et al (2010) Single infusion Pre/Post MADRS 00d4h -1.125 -1.750 -0.500 0.000
00d4h Ibrahim et al (2011) ECT-resistant (Single infusion) Pre/Post MADRS 00d4h -0.476 -0.736 -0.216 0.000
00d4h Ibrahim et al (2011) Non-ECT (Single infusion) Pre/Post MADRS 00d4h -0.966 -1.230 -0.701 0.000
00d4h Larkin et al (2011) Single infusion Pre/Post MADRS 00d4h -3.597 -5.017 -2.176 0.000
00d4h Salvadore et al (2012) Single infusion Pre/Post MADRS 00d4h -0.819 -1.398 -0.240 0.006
00d4h Thakurta et al (2012) Single infusion Pre/Post HDRS 00d4h -2.510 -3.354 -1.666 0.000
00d4h -1.290 -1.657 -0.924 0.000
01d Rybakowski et al (2013) Single infusion Pre/Post HDRS 01d -0.620 -1.037 -0.203 0.004
01d aan het Rot et al (2010) A Repeat infusion (Responders/Remitters) Pre/Post MADRS 01d -4.836 -7.147 -2.525 0.000
01d Zarate et al (2012a) A Single infusion Placebo/Ketamine MADRS 01d -0.662 -0.904 -0.420 0.000
01d Carlson et al (2013) A Single infusion Pre/Post MADRS 01d -0.906 -1.412 -0.401 0.000
01d Murrough et al (2012) A Repeat infusion (Responders/Remitters) Pre/Post MADRS 01d -3.639 -5.651 -1.627 0.000
01d Price et al (2009) Single infusion Pre/Post MADRS 01d -1.871 -2.501 -1.240 0.000
01d Diazgranados et al (2010) Single infusion Placebo/Ketamine MADRS 01d -0.636 -0.850 -0.422 0.000
01d Zarate et al (2006) Single infusion Placebo/Ketamine MADRS 01d -1.395 -1.883 -0.907 0.000
01d Mathew et al (2010) Single infusion Pre/Post MADRS 01d -2.046 -2.840 -1.252 0.000
01d Adballah et al (2012) Single infusion Pre/Post HDRS 01d -1.501 -2.460 -0.541 0.002
01d Sos et al (2013) Single infusion Placebo/Ketamine MADRS 01d -0.973 -1.422 -0.524 0.000
01d Murrough et al (2013) Single infusion Placebo/Ketamine MADRS 01d -0.817 -1.315 -0.318 0.001
01d Lapidus et al (2014) Single infusion Placebo/Ketamine MADRS 01d -1.962 -2.740 -1.184 0.000
01d -1.244 -1.560 -0.928 0.000
07d Rybakowski et al (2013) A Single infusion Pre/Post HDRS 07d -1.396 -1.938 -0.854 0.000
07d Loo et al (2012) ECT+ketamine (Repeat infusions) Pre/Post MADRS 07d -1.955 -2.659 -1.251 0.000
07d Zarate et al (2006) A Single infusion Placebo/Ketamine MADRS 07d -0.650 -1.138 -0.161 0.009
07d Sos et al (2013) A Single infusion Placebo/Ketamine MADRS 07d -0.698 -1.109 -0.287 0.001
07d Thakurta et al (2012) A Single infusion Pre/Post HDRS 07d -0.247 -0.675 0.180 0.257
07d Permoda-Osip et al (2013) Single infusion Pre/Post HDRS 07d -1.903 -2.912 -0.895 0.000
07d -1.060 -1.572 -0.547 0.000
12-14d Rybakowski et al (2013) B Single infusion Pre/Post HDRS 12-14d -1.551 -2.124 -0.977 0.000
12-14d Price et al (2009) A Repeat infusions (Responder/Remitters) Pre/Post MADRS 12-14d -4.516 -6.574 -2.457 0.000
12-14d Diazgranados et al (2010) A Single infusion Placebo/Ketamine MADRS 12-14d -0.210 -0.436 0.016 0.069
12-14d Loo et al (2012) A ECT+ketamine (Repeat infusions) Pre/Post MADRS 12-14d -1.730 -2.381 -1.079 0.000
12-14d -1.669 -2.850 -0.488 0.006
Overall -1.242 -1.455 -1.028 0.000
-5.00 -2.50 0.00 2.50 5.00
Favours A Favours B
Meta Analysis
Fig. 2  Forest Plot for Moderating Effect of Time-point for All Studies 
 
